Considerations on the improvement of height benefit in children with central precocious puberty

LIANG Li-Yang

doi:10.7499/j.issn.1008-8830.2308078

PDF(558 KB)

HTML

Chinese Journal of Contemporary Pediatrics ›› 2024, Vol. 26 ›› Issue (1) : 19-24. DOI: 10.7499/j.issn.1008-8830.2308078

SERIES LECTURE—STANDARDIZED DIAGNOSIS AND TREATMENT OF SHORT STATURE IN CHILDREN

Considerations on the improvement of height benefit in children with central precocious puberty

LIANG Li-Yang

Author information +

History +

Abstract

With the changes in various factors such as genetics and the environment, the incidence of childhood precocious puberty has been gradually increasing. Improving height is one of the key issues in the clinical management of precocious puberty. Currently, gonadotropin-releasing hormone analogs (GnRHa) remain the preferred treatment for precocious puberty, but their effect on height improvement is influenced by multiple factors, which may result in lower-than-expected height benefits. Combining recombinant human growth hormone (rhGH) therapy with GnRHa treatment is an alternative strategy to enhance the efficacy of GnRHa, but there is still no clear recommendation regarding the timing of their combination. Considering the current status of precocious puberty treatment, it is crucial to reevaluate the effects of GnRHa monotherapy and combination therapy with rhGH on height improvement. This article discusses strategies such as combination therapy indications to guide clinical medication and help children with precocious puberty achieve optimal height benefits.

Key words

Precocious puberty / Height benefit / Gonadotropin-releasing hormone analog / Growth hormone / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LIANG Li-Yang. Considerations on the improvement of height benefit in children with central precocious puberty[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(1): 19-24 https://doi.org/10.7499/j.issn.1008-8830.2308078

References

1 Bradley SH, Lawrence N, Steele C, et al. Precocious puberty[J]. BMJ, 2020, 368: l6597. PMID: 31932347. DOI: 10.1136/bmj.l6597.
2 Shu W, Zong X, Li H. Secular trends in age at pubertal onset assessed by breast development among Chinese girls: a systematic review[J]. Front Endocrinol (Lausanne), 2022, 13: 1042122. PMID: 36506059. PMCID: PMC9729541. DOI: 10.3389/fendo.2022.1042122.
3 中华医学会儿科学分会内分泌遗传代谢学组, 中华儿科杂志编辑委员会. 中枢性性早熟诊断与治疗专家共识（2022）[J]. 中华儿科杂志, 2023, 61(1): 16-22. PMID: 36594116. DOI: 10.3760/cma.j.cn112140-20220802-00693.
4 中华预防医学会妇女保健分会青春期学组. 女性性早熟的诊治共识[J]. 中国妇幼健康研究, 2018, 29(2): 135-138. DOI: 10.3969/j.issn.1673-5293.2018.02.001.
5 Liu M, Cao B, Luo Q, et al. The critical BMI hypothesis for puberty initiation and the gender prevalence difference: evidence from an epidemiological survey in Beijing, China[J]. Front Endocrinol (Lausanne), 2022, 13: 1009133. PMID: 36387887. PMCID: PMC9641365. DOI: 10.3389/fendo.2022.1009133.
6 中华医学会儿科学分会内分泌遗传代谢学组,《中华儿科杂志》编辑委员会. 中枢性性早熟诊断与治疗共识（2015）[J]. 中华儿科杂志, 2015, 53(6): 412-418. PMID: 26310550. DOI: 10.3760/cma.j.issn.0578-1310.2015.06.004.
7 De Sanctis V, Soliman AT, Di Maio S, et al. Long-term effects and significant adverse drug reactions (ADRs) associated with the use of gonadotropin-releasing hormone analogs (GnRHa) for central precocious puberty: a brief review of literature[J]. Acta Biomed, 2019, 90(3): 345-359. PMID: 31580327. PMCID: PMC7233750. DOI: 10.23750/abm.v90i3.8736.
8 Shi Y, Ma Z, Yang X, et al. Gonadotropin-releasing hormone analogue and recombinant human growth hormone treatment for idiopathic central precocious puberty in girls[J]. Front Endocrinol (Lausanne), 2022, 13: 1085385. PMID: 36589818. PMCID: PMC9794601. DOI: 10.3389/fendo.2022.1085385.
9 Cho AY, Shim YS, Lee HS, et al. Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty[J]. Sci Rep, 2023, 13(1): 1264. PMID: 36690835. PMCID: PMC9870989. DOI: 10.1038/s41598-023-28602-3.
10 杜敏联, 傅君芬. 对生长迟缓和生长追赶的再认识[J]. 中华儿科杂志, 2022, 60(3): 173-176. PMID: 35240734. DOI: 10.3760/cma.j.cn112140-20210903-00736.
11 Ni MM, Yang ST, Wu WW, et al. Benefits from the first year of GnRHa therapy in boys with idiopathic central precocious puberty when initiating treatment after age 9 years: findings from a real-world retrospective study[J]. BMC Endocr Disord, 2022, 22(1): 299. PMID: 36456936. PMCID: PMC9716691. DOI: 10.1186/s12902-022-01207-z.
12 Bangalore Krishna K, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium[J]. Horm Res Paediatr, 2019, 91(6): 357-372. PMID: 31319416. DOI: 10.1159/000501336.
13 Latronico AC, Brito VN, Carel JC. Causes, diagnosis, and treatment of central precocious puberty[J]. Lancet Diabetes Endocrinol, 2016, 4(3): 265-274. PMID: 26852255. DOI: 10.1016/S2213-8587(15)00380-0.
14 Baek JW, Nam HK, Jin D, et al. Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty[J]. Ann Pediatr Endocrinol Metab, 2014, 19(1): 27-31. PMID: 24926460. PMCID: PMC4049550. DOI: 10.6065/apem.2014.19.1.27.
15 储昭乐, 江辉, 吴倩. 促性腺激素释放激素类似物治疗对中枢性性早熟和快速进展型青春期患儿成年终身高改善的Meta分析[J]. 中国当代儿科杂志, 2021, 23(11): 1161-1168. PMID: 34753549. PMCID: PMC8580025. DOI: 10.7499/j.issn.1008-8830.2108078.
16 Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity[J]. J Clin Endocrinol Metab, 2007, 92(9): 3483-3489. PMID: 17579199. DOI: 10.1210/jc.2007-0321.
17 Donbalo?lu Z, Bedel A, ?etiner EB, et al. Effects of the gonadotropin-releasing hormone agonist therapy on growth and body mass index in girls with idiopathic central precocious puberty[J]. Acta Endocrinol (Buchar), 2022, 18(2): 181-186. PMID: 36212259. PMCID: PMC9512371. DOI: 10.4183/aeb.2022.181.
18 Korkmaz O, Sari G, Mecidov I, et al. The gonadotropin-releasing hormone analogue therapy may not impact final height in precocious puberty of girls with onset of puberty aged 6-8 years[J]. J Clin Med Res, 2019, 11(2): 133-136. PMID: 30701006. PMCID: PMC6340673. DOI: 10.14740/jocmr3710.
19 Castro C, Espada F, Leite AL, et al. Height benefit of GnRH agonists after age 8 in a Portuguese cohort of central precocious puberty[J]. Clin Endocrinol (Oxf), 2023, 98(5): 670-677. PMID: 36710456. DOI: 10.1111/cen.14884.
20 Vuralli D, Gonc NE, Ozon ZA, et al. Which parameters predict the beneficial effect of GnRHa treatment on height in girls with central precocious puberty?[J]. Clin Endocrinol (Oxf), 2021, 94(5): 804-810. PMID: 33460480. DOI: 10.1111/cen.14420.
21 中华医学会儿科学分会内分泌遗传代谢学组, 中华医学会儿科学分会儿童保健学组, 中华儿科杂志编辑委员会. 儿童体格发育评估与管理临床实践专家共识[J]. 中华儿科杂志, 2021, 59(3): 169-174. PMID: 33657689. DOI: 10.3760/cma.j.cn112140-20210116-00050.
22 Murato?lu ?ahin N, U?ra? Dikmen A, ?etinkaya S, et al. Subnormal growth velocity and related factors during GnRH analog therapy for idiopathic central precocious puberty[J]. J Clin Res Pediatr Endocrinol, 2018, 10(3): 239-246. PMID: 29687783. PMCID: PMC6083469. DOI: 10.4274/jcrpe.0023.
23 Kim MS, Koh HJ, Lee GY, et al. Comparing adult height gain and menarcheal age between girls with central precocious puberty treated with gonadotropin-releasing hormone agonist alone and those treated with combined growth hormone therapy[J]. Ann Pediatr Endocrinol Metab, 2019, 24(2): 116-123. PMID: 31261476. PMCID: PMC6603606. DOI: 10.6065/apem.2019.24.2.116.
24 黄飞轩, 李立, 罗剑平. 促性腺激素释放激素类似物与重组人生长激素联合治疗小儿特发性中枢性性早熟的初步研究[J]. 广州医科大学学报, 2016, 44(3): 86-88. DOI: 10.3969/j.issn.1008-1836.2016.03.024.
25 李燕虹, 朱顺叶, 马华梅, 等. 促性腺激素释放激素类似物联合司坦唑醇治疗改善大骨龄特发性中枢性性早熟女孩成年身高的疗效评价[J]. 中华儿科杂志, 2013, 51(11): 807-812. PMID: 24484553. DOI: 10.3760/cma.j.issn.0578-1310.2013.11.002.
26 马晓宇, 倪继红, 杨露露, 等. GnRHa治疗对特发性中枢性性早熟和快速进展型早发育儿童的远期影响[J]. 中华内分泌代谢杂志, 2020, 36(1): 58-62. DOI: 10.3760/cma.j.issn.1000-6699.2020.01.008.
27 Fu J, Zhang J, Chen R, et al. Long-term outcomes of treatments for central precocious puberty or early and fast puberty in Chinese girls[J]. J Clin Endocrinol Metab, 2020, 105(3): dgz027. PMID: 31702013. DOI: 10.1210/clinem/dgz027.
28 罗小平. 身材矮小症儿童诊疗规范[M]. 北京: 人民卫生出版社, 2019: 63-67.
29 中华医学会儿科学分会内分泌遗传代谢学组. 矮身材儿童诊治指南[J]. 中华儿科杂志, 2008, 46(6): 428-430. PMID: 19099778. DOI: 10.3321/j.issn:0578-1310.2008.06.007.
30 罗小丹. GnRHa联合重组人生长激素治疗特发性中枢性性早熟女童的临床效果[J]. 中国当代医药, 2015, 22(3): 107-109.
31 中华医学会儿科学分会内分泌遗传代谢学组, 《中华儿科杂志》编辑委员会, 梁雁. 基因重组人生长激素儿科临床规范应用的建议[J]. 中华儿科杂志, 2013, 51(6): 426-432. PMID: 24120059. DOI: 10.3760/cma.j.issn.0578-1310.2013.06.007.
32 中华医学会儿科学分会内分泌遗传代谢学组, 中华儿科杂志编辑委员会. 过渡期生长激素缺乏症诊断及治疗专家共识[J]. 中华儿科杂志, 2020, 58(6): 455-460. PMID: 32521956. DOI: 10.3760/cma.j.cn112140-20200314-00237.